EHA 2023 | AL amyloidosis: current and prospective treatments
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses the current state of treatment for light chain (AL) amyloidosis. Whilst dara-CyBorD has revolutionized the treatment of newly diagnosed AL amyloidosis, treatment options for patients with stage IIIb disease remain scarce. Daratumumab monotherapy appears to be efficacious in this patient population, and several prospective studies are investigating other antibody-based treatments that enhance amyloid absorption. Dr Kastritis emphasizes the importance of achieving a complete hematologic response with undetectable measurable residual disease (MRD) to achieve the best possible outcomes. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
GSK: Honoraria; Takeda: Honoraria; Pfizer: Honoraria, Research Funding; Genesis Pharma: Honoraria; Janssen: Honoraria, Research Funding; Amgen: Honoraria, Research Funding.
